Efficacy and Safety of Orally and Intravenously Administration of Tranexamic Acid in Patients with Elderly Femoral Neck Fracture

Abstract

Objective: For elderly femoral neck fracture patients, anemia is one of the most common complications, increasing the risk of postoperative adverse events. Tranexamic acid (TXA) has been widely applied to the perioperative blood management. However, the optimal route of TXA administration in elderly femoral neck fracture remains unclear. The aim of this study is to evaluate the efficacy and safety of oral and intravenous (IV) application of TXA in elderly patients with femoral neck fracture undergoing total hip arthroplasty (THA) and hemiarthroplasty (HA).

Methods: All elderly patients aged over 65 years old diagnosed with femoral neck fracture admitted to the trauma orthopedics from August 1, 2020 to February 28, 2022 were enrolled in this prospective cohort study. Participants were divided into three groups: oral group: TXA 2g orally 2 h before incision; IV group: intravenous infusion of TXA 1g 15 min before incision; and control group: usual hemostatic method. The primary outcomes were total blood loss, allogeneic transfusion rate, and postoperative thromboembolic events. SPSS 23.0 (IBM, Armonk, NY, USA) was used for statistical analysis, and p ≤ 0.05 was considered statistically significant.

Results: A total of 100 patients were enrolled, including 32 cases in the oral group, 34 cases in the IV group and 34 cases in the control group. Compared with the control group, the total perioperative blood loss in the oral and IV groups was significantly decreased (763.92 ± 358.64 mL vs 744.62 ± 306.88 mL vs 1250.60 ± 563.37 mL, p = 0.048). No significant difference was identified between the oral and IV groups (p = 0.970). The rate of allogeneic transfusion was lower in the oral and IV groups than in the control group, but the difference had no statistical significant (6 vs 5 vs 12, p = 0.108), However, subgroup analysis showed that the IV and oral groups in patients who underwent THA have significant lower transfusion rate compared with the control group (1 vs 3 vs 7, p = 0.02). During 6 months follow-up, no thromboembolic events were identified. Two patients (one from the oral group and one from the control group) died of respiratory failure. The cost of blood management from the oral group was significantly lower than IV (p < 0.001) and control groups (p = 0.009).

Conclusion: Elderly patients with femoral neck fracture undergoing THA can benefit from both IV and oral administration of tranexamic acid. The results of these two administration routes are similar in safety and effectiveness. A similar tendency was observed in patients undergoing HA. Oral TXA is more cost–benefit compared with intravenous applications.

Keywords

Elderly / Femoral neck fracture / Hip arthroplasty / Oral application / Tranexamic acid

References

[1] Burgers PT, Hoogendoorn M, Van Woensel EA, Poolman RW, Bhandari M, Patka P, et al. Total medical costs of treating femoral neck fracture patients with hemi-or total hip arthroplasty: a cost analysis of a multicenter prospective study. Osteoporos Int. 2016; 27(6): 1999–2008.

[2] Ackermann L, Schwenk ES, Lev Y, Weitz H. Update on medical management of acute hip fracture. Cleve Clin J Med. 2021; 88(4): 237–247.

[3] Liu YM, Huang H, Gao J, Zhou J, Chu HC. Hemoglobin concentration and post-operative delirium in elderly patients undergoing femoral neck fracture surgery. Front Med (Lausanne). 2021; 8: 780196.

[4] Smith GH, Tsang J, Molyneux SG, White TO. The hidden blood loss after hip fracture. Injury. 2011; 42(2): 133–135.

[5] Yombi JC, Putineanu DC, Cornu O, Lavand’homme P, Cornette P, Castanares-Zapatero D. Low haemoglobin at admission is associated with mortality after hip fractures in elderly patients. Bone Joint J. 2019; 101-b(9): 1122–1128.

[6] Sinclair RCF, Moppett IK, Gillies MA. Patient blood management and hip fracture. Anaesthesia. 2021; 76(3): 417–418.

[7] Bielza R, Mora A, Zambrana F, Sanjurjo J, Sanz-Rosa D, Thuissard IJ, et al. Impact of a patient blood management program within an orthogeriatric care service. Transfus Apher Sci. 2018; 57(4): 517–523.

[8] Arshi A, Lai WC, Iglesias BC, McPherson EJ, Zeegen EN, Stavrakis AI, et al. Blood transfusion rates and predictors following geriatric hip fracture surgery. Hip Int. 2021; 31(2): 272–279.

[9] Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015; 70(Suppl 1): 50–53 e18.

[10] Cheung ZB, Anthony SG, Forsh DA, Podolnick J, Zubizarreta N, Galatz LM, et al. Utilization, effectiveness, and safety of tranexamic acid use in hip fracture surgery: a population-based study. J Orthop. 2020; 20: 167–172.

[11] Wu Y, Zeng Y, Hu Q, Li M, Bao X, Zhong J, et al. Blood loss and cost-effectiveness of oral vs intravenous tranexamic acid in primary total hip arthroplasty: a randomized clinical trial. Thromb Res. 2018; 171: 143–148.

[12] Qi Y, Li Y, Wang C, Chen H, Rui Y. Comparison of oral and intravenous tranexamic acid in total hip arthroplasty: a systematic review and meta-analysis. Art Ther. 2020; 2(1): 9.

[13] Li RY, Xie T, Zhao YK, Qi YM, Li YJ, Wang Z, et al. Oral versus intravenous tranexamic acid in elderly patients with intertrochanteric fracture undergoing proximal femur intramedullary nailing: a prospective cohort study. J Orthop Translat. 2022; 34: 85–90.

[14] Xie J, Hu Q, Ma J, Huang Q, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial. Bone Joint J. 2017; 99-b(11): 1442–1449.

[15] Zhang S, Xie J, Cao G, Lei Y, Huang Q, Pei F. Six-dose intravenous tranexamic acid regimen further inhibits postoperative fibrinolysis and reduces hidden blood loss following Total knee arthroplasty. J Knee Surg. 2021; 34(2): 224–232.

[16] Zhou ZK, Wong XS, Xiang B. Expert consensus in enhanced recovery after total hip and knee arthroplasty in China: diagnosis and treatment of perioperative anemia. Chin J Bone Joint Surg. 2016; 9(1): 10–15.

[17] Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962; 51(2): 224–232.

[18] Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983; 58(3): 277–280.

[19] Shichman I, Shaked O, Ashkenazi I, Schwarzkopf R, Warschawski Y, Snir N. Tranexamic acid in non-elective primary total hip arthroplasty. Injury. 2021; 52(6): 1544–1548.

[20] Ashkenazi I, Schermann H, Gold A, Lin R, Pardo I, Steinberg E, et al. Tranexamic acid in hip hemiarthroplasty. Injury. 2020; 51(11): 2658–2662.

[21] Maezawa K, Nozawa M, Maruyama Y, Sakuragi E, Sugimoto M, Ishijima M. Comparison of anemia, renal function, and nutritional status in older women with femoral neck fracture and older women with osteoarthritis of the hip joint. J Orthop Sci. 2022; 28: 380–384.

[22] Grassin-Delyle S, Semeraro M, Lamy E, Urien S, Runge I, Foissac F, et al. Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. Br J Anaesth. 2022; 128(3): 465–472.

[23] Luo ZY, Wang HY, Wang D, Zhou K, Pei FX, Zhou ZK. Oral vs intravenous vs topical tranexamic acid in primary hip arthroplasty: a prospective, randomized, double-blind, controlled study. J Arthroplasty. 2018; 33(3): 786–793.

[24] Liu W, Deng S, Liang J. Tranexamic acid usage in hip fracture surgery: a meta-analysis and meta-regression analysis of current practice. Arch Orthop Trauma Surg. 2021; 142: 2769–2789.

[25] Adams JD Jr, Marshall WA. The use of tranexamic acid in hip and pelvic fracture surgeries. J Am Acad Orthop Surg. 2021; 29(12): e576–e583.

[26] Zhao YK, Zhang C, Zhang YW, Li RY, Xie T, Bai LY, et al. Efficacy and safety of tranexamic acid in elderly patients with femoral neck fracture treated with hip arthroplasty: a systematic review and meta-analysis. J Orthop Sci. 2023; 29: 542–551.

[27] Effects of tranexamic acid on death. Disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019; 394(10210): 1713–1723.

[28] Nikolaou VS, Masouros P, Floros T, Chronopoulos E, Skertsou M, Babis GC. Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial. Bone Joint J. 2021; 103-b(3): 442–448.

[29] van Rijckevorsel V, Roukema GR, Kuijper TM, de Jong L. Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients. Orthop Traumatol Surg Res. 2022; 108: 103219.

[30] Liu J, Lei Y, Liao J, Liang X, Hu N, Huang W. Pre-Emptive Antifibrinolysis: its role and efficacy in hip fracture patients undergoing Total hip arthroplasty. J Arthroplasty. 2022; 37(4): 755–762.

[31] Porter SB, Spaulding AC, Duncan CM, Wilke BK, Pagnano MW, Abdel MP. Tranexamic acid was not associated with increased complications in high-risk patients with hip fracture undergoing arthroplasty. J Bone Joint Surg Am. 2021; 103(20): 1880–1889.

[32] McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012; 72(5): 585–617.

RIGHTS & PERMISSIONS

2024 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.